Clinical Trials Browser

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06388902 2025-11-21

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Phase 1 Suspended

120 enrolled

Advanced Solid Malignancies

NCT05938296 2025-11-19

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

Phase 1 Suspended

29 enrolled

Other solid neoplasm

Solid Tumor

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

150 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03392064 2025-10-15

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

Phase 1 Suspended

6 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05494697 2025-10-14

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Phase 2 Suspended

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03417921 2025-10-01

Pancreatic

Phase 1/2 Suspended

60 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04693546 2025-09-26

PREVENT

Suspended

12,000 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1 Suspended

71 enrolled

DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05055518 2025-06-27

APL-102 Capsule in Patients With Advanced Solid Tumors

Phase 1 Suspended

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05958199 2025-06-27

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Phase 1 Suspended

131 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05603572 2025-06-05

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Phase 1/2 Suspended

148 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular

NCT02354547 2025-05-30

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Phase 1 Suspended

18 enrolled

Tumor-Agnostic

Neoplasms

NCT05571969 2025-05-07

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Phase 1 Suspended

40 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

PINNACLE

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

ALIVE

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Pancreatic

PREVENT

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

APL-102 Capsule in Patients With Advanced Solid Tumors

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors